Secure CheckoutPersonal information is secured with SSL technology.
Free ShippingFree global shipping
No minimum order.
1. Targeting Members of the Epidermal Growth Factor Receptor Family to Improve Response to Chemotherapy
2. Targeting the Hepatocyte Growth Factor Receptor to Overcome Resistance to Targeted Therapies
3. Roles for AXL and MERTK in Resistance to Cytotoxic and Targeted Therapies
4. The JNK Pathway in Drug Resistance
5. Fibroblast Growth Factor Receptor (FGFR) Inhibitors: Enhancing Therapeutic Strategies for Solid Tumors
6. PIK3CA Mutations in Colorectal and Breast Cancer: Impact on Oncogenesis and Response to Nonsteroidal Anti-inflammatory Drugs
7. STAT3 as a Major Contributor to Chemoresistance
8. Targeting the Hippo Pathway to Improve Response to Chemotherapy
9. Modulation of the Epigenome (Methylome) to Improve Chemotherapeutic Efficacy
10. Targeting the ATR Signaling Pathway to Overcome Chemoresistance in Cancer
11. PARP Inhibition to Enhance Response to Chemotherapy
12. Autophagy Inhibition and Chemosensitization in Cancer Therapy
13. Targeting Necroptosis in Anti-Tumor Therapy
Targeting Cell Survival Pathways to Enhance Response to Chemotherapy encompasses recently developed molecular targeting agents and approaches that suppress cell survival signaling. Cell survival signaling attenuates the effectiveness of conventional chemotherapy and numerous mechanisms have been described, and continue to be described, which contribute to cell survival in the face of chemotherapy treatment.
Key pathways leading to chemoresistance emanate from growth factor receptors, PI3K, STAT3, anti-apoptotic Bcl-2 family members, autophagy, and the DNA damage response pathway. New advances have underscored the potential of targeting each of these cell survival mechanisms to improve responsiveness to chemotherapy. This book reviews these recent advances and provides a foundational background and hints of new opportunities for basic, translational, and clinical investigators focused on improving therapeutic responses to chemotherapy.
- Presents cutting-edge agents and approaches with proved success in different model systems that can be translated to a different type of cancer
- Brings updated information to be used to propose new clinical trials investigating innovative strategies for improving responses to chemotherapy
- Provides mechanistic details to help guide the design of laboratory studies associated with clinical trials
Cancer researchers; medical oncologists; clinicians; translational investigators
- No. of pages:
- © Academic Press 2019
- 3rd April 2018
- Academic Press
- Hardcover ISBN:
- eBook ISBN:
Benjamin Bonavida, PhD, has been involved in the field of immunology and cancer biology for several decades and has published extensively in the fields of cancer resistance, chemotherapy, immunotherapy, and various molecular approaches to circumvent the resistance of the cancer cells using sensitizing agents. Accordingly, he was the first to publish a book on tumor sensitization in 2008. More recently, Dr. Bonavida is the Series Editor of 3 series published by Elsevier/Academic Press (“Cancer Sensitizing Agents for Chemotherapy,” “Breaking Cancer Resistance to Therapeutic Antibodies,” and “Breaking Tolerance to Anti-Cancer Immunotherapy”) and several books have been published and many are in development. He has published extensively in the field of NK biology and cytotoxicity in the past, and many of these publications were in collaboration with the co-editor Dr. Anahid Jewett.
Professor, Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, USA
Daniel E. Johnson received his undergraduate degrees in chemistry and mathematics from North Park University in Chicago, Illinois. He received his doctoral degree in molecular biology from Princeton University under the mentorship of Dr. Mark A. Bothwell. His postdoctoral research was done under the mentorship of Dr. Lewis T. Williams at the University of California at San Francisco (UCSF). He joined the faculty at the University of Pittsburgh and the University of Pittsburgh Cancer Institute in 1993, where he served as Professor of Medicine and Scientific Director of the Acute Leukemia Working Group. In 2016, he moved to UCSF where he is currently Professor in the Department of Otolaryngology – Head and Neck Surgery. Dr. Johnson has served as a standing member on National Institutes of Health and American Cancer Society study sections and has been a Section Editor for the journal Leukemia since 2001. His research is focused on anti-cancer drug development and the elucidation of cell death and cell survival signaling pathways in head and neck cancer and leukemia. He has additional interests in the development of chemopreventive agents and strategies. Dr. Johnson places particular emphasis on translating laboratory findings to the clinic and has collaborated extensively with physician scientists to initiate and conduct clinical trials in head and neck cancer and acute myeloid leukemia. .
Professor, Department of Otolaryngology-Head and Neck Surgery, University of California, San Francisco, USA
Elsevier.com visitor survey
We are always looking for ways to improve customer experience on Elsevier.com.
We would like to ask you for a moment of your time to fill in a short questionnaire, at the end of your visit.
If you decide to participate, a new browser tab will open so you can complete the survey after you have completed your visit to this website.
Thanks in advance for your time.